| abaloparatide | Approved (phase 4) | Phase 4 | 6 | February 2027 NCT03841058 | Hospital for Special Surgery, New York, State University of New York at Buffalo | 2017 |
| abarelix | Approved (phase 4) | — | 0 | — | — | 2003 |
| aclerastide | Phase 3 | — | 0 | — | — | — |
| act-1 peptide | Phase 3 | — | 0 | — | — | — |
| afamelanotide | Approved (phase 4) | Phase 3 | 1 | December 2025 NCT06109649 | Clinuvel, Inc. | 2014 |
| albiglutide | Approved (phase 4) | — | 1 | May 31, 2026 NCT05220917 | Brigham and Women's Hospital | 2014 |
| albuvirtide | Phase 3 | — | 2 | July 2028 NCT07727642 | Shanghai Public Health Clinical Center, Shanxi Bethune Hospital | — |
| alizulatide vixocianine | Phase 2 | — | 0 | — | — | — |
| almurtide | Phase 2 | — | 0 | — | — | — |
| alsactide | Phase 2 | — | 0 | — | — | — |
| amilomotide | Phase 2 | — | 0 | — | — | — |
| amlintide | Phase 2 | — | 1 | October 2026 NCT07506369 | University Hospital, Gentofte, Copenhagen | — |
| anamorelin | Phase 3 | Phase 3 | 2 | December 31, 2026 NCT03637816 | M.D. Anderson Cancer Center | — |
| anaritide acetate | Phase 2 | — | 0 | — | — | — |
| anfibatide | Phase 2 | — | 0 | — | — | — |
| argipressin tannate | Phase 2 | — | 0 | — | — | — |
| argiprestocin | Phase 2 | — | 0 | — | — | — |
| aspartocin | Phase 2 | — | 0 | — | — | — |
| avexitide | Phase 3 | Phase 3 | 1 | July 8, 2026 NCT06747468 | Amylyx Pharmaceuticals Inc. | — |
| avorelin | Phase 2 | — | 0 | — | — | — |
| azetirelin | Phase 2 | — | 0 | — | — | — |
| balixafortide | Phase 3 | Phase 1 | 1 | February 2027 NCT06981806 | Arsen Osipov | — |
| baloramotide | Phase 2 | — | 0 | — | — | — |
| betiatide | Phase 2 | — | 0 | — | — | — |
| bevemipretide | Phase 2 | — | 0 | — | — | — |
| bibapcitide | Phase 2 | — | 0 | — | — | — |
| bofanglutide | Phase 2 | Phase 3 | 2 | October 2027 NCT07628985 | Carnot Laboratories | — |
| bremelanotide | Approved (phase 4) | Phase 2 | 1 | February 5, 2025 NCT06565611 | Palatin Technologies, Inc | 2019 |
| brimapitide | Phase 3 | — | 0 | — | — | — |
| bulevirtide | Approved (phase 4) | Phase 3 | 10 | November 2026 NCT07142811 | Vir Biotechnology, Inc., Mirum Pharmaceuticals, Inc. | 2020 |
| buserelin | Approved (phase 4) | Phase 3 | 3 | November 11, 2026 NCT05050084 | NRG Oncology, Proton Collaborative Group | — |
| cagrilintide | Phase 3 | Phase 3 | 16 | March 1, 2027 NCT07011667 | Novo Nordisk A/S | — |
| canvuparatide | Phase 2 | Phase 3 | 1 | January 2028 NCT07699471 | MBX Biosciences | — |
| capromab pendetide | Approved (phase 4) | — | 0 | — | — | 1996 |
| capromorelin | Phase 2 | — | 0 | — | — | — |
| carbetocin | Approved (phase 4) | Phase 4 | 14 | March 1, 2028 NCT07401524 | Sheba Medical Center, Mansoura University | — |
| cargutocin | Phase 2 | — | 0 | — | — | — |
| carperitide | Phase 3 | — | 0 | — | — | — |
| cenderitide | Phase 2 | — | 0 | — | — | — |
| certepetide | Phase 2 | Phase 2 | 2 | September 2025 NCT05121038 | Anup Kasi, Qilu Pharmaceutical Co., Ltd. | — |
| ceruletide | Approved (phase 4) | — | 0 | — | — | 1982 |
| ceruletide diethylamine | Approved (phase 4) | — | 0 | — | — | 1982 |
| cetrorelix | Approved (phase 4) | Phase 4 | 8 | December 2026 NCT07350317 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Trust Fertility Clinic | 1999 |
| cibinetide | Phase 2 | — | 0 | — | — | — |
| cilengitide | Phase 3 | — | 0 | — | — | — |
| codactide | Phase 2 | — | 0 | — | — | — |
| copper (64cu) adarulatide tetraxetan | Phase 2 | — | 0 | — | — | — |
| copper oxodotreotide | Approved (phase 4) | — | 0 | — | — | 2020 |
| copper oxodotreotide cu-64 | Approved (phase 4) | — | 0 | — | — | 2020 |
| corticorelin | Phase 3 | Phase 1 | 2 | July 24, 2022 NCT04037605 | Peter y. Liu, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | — |
| corticorelin ovine triflutate | Approved (phase 4) | — | 0 | — | — | 1996 |
| cotadutide | Phase 2 | — | 0 | — | — | — |
| dalazatide | Phase 2 | — | 0 | — | — | — |
| danegaptide | Phase 3 | — | 0 | — | — | — |
| dapiglutide | Phase 2 | Phase 2 | 1 | April 24, 2024 NCT05788601 | University Hospital, Gentofte, Copenhagen | — |
| davalintide | Phase 2 | — | 0 | — | — | — |
| davunetide | Phase 2 | — | 0 | — | — | — |
| dazdotuftide | Phase 3 | — | 0 | — | — | — |
| degarelix | Approved (phase 4) | Phase 4 | 40 | November 2026 NCT03951831 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Colorado, Denver | 2008 |
| delmitide | Phase 2 | — | 0 | — | — | — |
| demoxytocin | Phase 2 | — | 0 | — | — | — |
| depreotide | Approved (phase 4) | — | 0 | — | — | 1999 |
| deslorelin | Phase 2 | — | 0 | — | — | — |
| desmopressin | Approved (phase 4) | Phase 4 | 14 | February 2027 NCT06337838 | Hospital de Clinicas de Porto Alegre, Medical University of Bialystok | 1978 |
| detirelix acetate | Phase 2 | — | 0 | — | — | — |
| diamfenetide | Phase 2 | — | 0 | — | — | — |
| diclometide | Phase 2 | — | 0 | — | — | — |
| dirucotide | Phase 3 | — | 0 | — | — | — |
| disaccharide tripeptide glycerol dipalmitoyl | Phase 2 | — | 0 | — | — | — |
| disitertide | Phase 2 | — | 0 | — | — | — |
| disomotide | Phase 2 | — | 0 | — | — | — |
| dolcanatide | Phase 2 | — | 0 | — | — | — |
| doreptide | Phase 2 | — | 0 | — | — | — |
| dulaglutide | Approved (phase 4) | Phase 4 | 15 | October 1, 2026 NCT06257966 | Eli Lilly and Company, National University of Singapore | 2014 |
| dumorelin | Phase 2 | — | 0 | — | — | — |
| dusquetide | Phase 3 | — | 0 | — | — | — |
| ebiratide | Phase 2 | — | 0 | — | — | — |
| ecallantide | Approved (phase 4) | — | 0 | — | — | 2009 |
| ecnoglutide | Phase 3 | Phase 3 | 7 | November 30, 2026 NCT07553299 | Hangzhou Sciwind Biosciences Co., Ltd., Verdiva Bio Dev Limited | — |
| ederimotide | Phase 2 | — | 0 | — | — | — |
| edotreotide | Phase 3 | Phase 3 | 4 | June 2027 NCT04919226 | ITM Solucin GmbH, Grupo Espanol de Tumores Neuroendocrinos | — |
| edotreotide gallium ga-68 | Approved (phase 4) | — | 0 | — | — | 2016 |
| edotreotide yttrium | Phase 2 | — | 0 | — | — | — |
| edotreotide yttrium y-90 | Phase 2 | — | 0 | — | — | — |
| edratide | Phase 2 | — | 0 | — | — | — |
| efinopegdutide | Phase 2 | — | 0 | — | — | — |
| efmedaglutide alfa | Phase 2 | — | 0 | — | — | — |
| efocipegtrutide | Phase 2 | — | 0 | — | — | — |
| efpeglenatide | Phase 3 | — | 0 | — | — | — |
| efsubaglutide alfa | Phase 2 | Phase 4 | 6 | November 30, 2026 NCT07163650 | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| elamipretide | Phase 3 | Phase 4 | 3 | August 2027 NCT06373731 | Stealth BioTherapeutics Inc., David Marcinek | — |
| eloralintide | Phase 2 | Phase 3 | 15 | March 2027 NCT07215559 | Eli Lilly and Company | — |
| elpamotide | Phase 2 | — | 0 | — | — | — |
| elsiglutide | Phase 2 | — | 0 | — | — | — |
| emideltide | Phase 2 | — | 0 | — | — | — |
| enavermotide | Phase 2 | — | 0 | — | — | — |
| eneboparatide | Phase 2 | Phase 3 | 1 | November 15, 2024 NCT05778071 | Alexion Pharmaceuticals, Inc. | — |
| enfuvirtide | Approved (phase 4) | — | 0 | — | — | 2003 |
| enlicitide | Phase 3 | Phase 3 | 8 | October 12, 2027 NCT07614984 | Merck Sharp & Dohme LLC | — |
| enlicitide chloride | Phase 2 | — | 0 | — | — | — |
| enlicitide decanoate | Phase 3 | Phase 3 | 7 | October 12, 2027 NCT07614984 | Merck Sharp & Dohme LLC | — |
| ensereptide | Phase 2 | — | 0 | — | — | — |
| eptifibatide | Approved (phase 4) | Phase 3 | 1 | September 30, 2029 NCT07347626 | Xinqiao Hospital of Chongqing | 1998 |
| etarfolatide | Phase 2 | — | 0 | — | — | — |
| etelcalcetide | Approved (phase 4) | Phase 3 | 3 | June 30, 2027 NCT03969329 | Amgen | 2016 |
| etimumotide | Phase 2 | — | 0 | — | — | — |
| examorelin | Phase 2 | — | 0 | — | — | — |
| exenatide | Approved (phase 4) | Phase 4 | 8 | December 31, 2025 NCT05482789 | Seattle Children's Hospital, Maisa N. Feghali, MD | 2005 |
| felypressin | Phase 2 | — | 0 | — | — | — |
| fequesetide | Phase 2 | — | 0 | — | — | — |
| fertirelin | Phase 2 | — | 0 | — | — | — |
| fexapotide | Phase 3 | — | 0 | — | — | — |
| fexapotide triflutate | Phase 3 | — | 0 | — | — | — |
| fluciclatide | Phase 2 | — | 0 | — | — | — |
| fluciclatide f 18 | Phase 2 | — | 0 | — | — | — |
| froniglutide | Phase 2 | — | 0 | — | — | — |
| gallium (68ga) rofapitide tetraxetan | Phase 2 | — | 0 | — | — | — |
| gallium oxodotreotide | Approved (phase 4) | Phase 2 | 6 | November 2, 2026 NCT05691465 | OHSU Knight Cancer Institute, Mayo Clinic | 2016 |
| gallium rofapitidexetan | Phase 2 | — | 0 | — | — | — |
| ganipatide | Phase 2 | — | 0 | — | — | — |
| ganirelix | Approved (phase 4) | Phase 4 | 4 | October 31, 2026 NCT06745466 | University of Delaware | 1999 |
| gersizangitide | Phase 2 | — | 0 | — | — | — |
| ghrelin | Phase 3 | Phase 2 | 5 | December 16, 2007 NCT03338387 | Charles University, Czech Republic | — |
| giractide | Phase 2 | — | 0 | — | — | — |
| glepaglutide | Phase 3 | Phase 3 | 2 | September 18, 2028 NCT07228403 | Zealand Pharma | — |
| glisentide | Phase 2 | — | 0 | — | — | — |
| glucagon-like peptide ii | Phase 3 | — | 0 | — | — | — |
| gonadorelin | Approved (phase 4) | Phase 3 | 4 | December 2028 NCT04390646 | Nelly Pitteloud | 1982 |
| goralatide | Phase 2 | — | 0 | — | — | — |
| goserelin | Approved (phase 4) | Phase 4 | 69 | November 2026 NCT05607004 | City of Hope Medical Center, Fudan University | 1989 |
| gozetotide | Approved (phase 4) | Phase 3 | 12 | December 30, 2026 NCT06145633 | Jonsson Comprehensive Cancer Center, Fred Hutchinson Cancer Center | 2020 |
| gozetotide alf-18 | Phase 3 | — | 0 | — | — | — |
| hepalatide | Phase 2 | Phase 3 | 2 | June 2027 NCT07309380 | Shanghai HEP Pharmaceutical Co., Ltd. | — |
| histrelin | Approved (phase 4) | Phase 3 | 5 | November 11, 2026 NCT05050084 | NRG Oncology, VA Office of Research and Development | 1991 |
| human c-peptide | Phase 2 | — | 0 | — | — | — |
| icrocaptide | Phase 2 | — | 0 | — | — | — |
| ilatreotide | Phase 2 | — | 0 | — | — | — |
| imsamotide | Phase 2 | — | 0 | — | — | — |
| indium in 111 satumomab pendetide | Approved (phase 4) | — | 0 | — | — | 1991 |
| indium pentetreotide | Approved (phase 4) | — | 0 | — | — | 1994 |
| invopressin | Phase 2 | — | 0 | — | — | — |
| iodine i124 evuzamitide | Phase 2 | — | 0 | — | — | — |
| ipamorelin | Phase 2 | — | 0 | — | — | — |
| irucalantide | Phase 2 | — | 0 | — | — | — |
| iturelix | Phase 2 | — | 0 | — | — | — |
| lagatide | Phase 2 | — | 0 | — | — | — |
| lancovutide | Phase 2 | — | 0 | — | — | — |
| lanreotide | Approved (phase 4) | Phase 4 | 8 | November 2026 NCT05050942 | Grupo Espanol de Tumores Neuroendocrinos, Antonio Fojo | 2007 |
| larazotide | Phase 3 | — | 0 | — | — | — |
| lead (212pb) bamzireotide navoxetan | Phase 2 | — | 0 | — | — | — |
| lead (212pb) lapemelanotide zapixetan | Phase 2 | — | 0 | — | — | — |
| lead bamzireotide navoxetan | Phase 2 | — | 0 | — | — | — |
| lead lapemelanotide zapixetan | Phase 2 | — | 0 | — | — | — |
| leconotide | Phase 2 | — | 0 | — | — | — |
| lenomorelin | Phase 2 | — | 0 | — | — | — |
| linaclotide | Approved (phase 4) | Phase 4 | 7 | October 2026 NCT03119584 | University of Florida, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012 |
| liraglutide | Approved (phase 4) | Phase 4 | 30 | December 31, 2026 NCT03856632 | University of Virginia, 4Moving Biotech | 2009 |
| livoletide | Phase 2 | — | 0 | — | — | — |
| lixisenatide | Approved (phase 4) | Phase 4 | 5 | June 30, 2027 NCT07173712 | Yanbing Li, Sanofi | 2013 |
| lorutengitide | Phase 2 | — | 0 | — | — | — |
| lsalt peptide | Phase 3 | Phase 2 | 1 | March 2027 NCT05879432 | Arch Biopartners Inc. | — |
| lucicebtide | Phase 2 | — | 0 | — | — | — |
| lusupultide | Phase 2 | — | 0 | — | — | — |
| lutetium (177lu) tezuvotide tetraxetan | Phase 2 | — | 0 | — | — | — |
| lutetium (lu177) rofapitide tetraxetan | Phase 2 | — | 0 | — | — | — |
| lutetium lu 177 zadavotide guraxetan | Phase 2 | Phase 3 | 1 | June 4, 2029 NCT07611110 | AstraZeneca | — |
| lutetium oxodotreotide | Approved (phase 4) | Phase 2 | 10 | November 2, 2026 NCT05691465 | National Cancer Institute (NCI), OHSU Knight Cancer Institute | 2017 |
| lutetium oxodotreotide lu-177 | Approved (phase 4) | Phase 2 | 10 | November 2, 2026 NCT05691465 | National Cancer Institute (NCI), OHSU Knight Cancer Institute | 2017 |
| lutetium rofapitidexetan | Phase 2 | — | 0 | — | — | — |
| lutetium tezuvotidexetan | Phase 2 | — | 0 | — | — | — |
| lutrelin | Phase 2 | — | 0 | — | — | — |
| lypressin | Approved (phase 4) | — | 1 | June 30, 2024 NCT05266534 | Wael Elbanna Clinic | 1982 |
| macimorelin | Approved (phase 4) | — | 0 | — | — | 2017 |
| maraciclatide | Phase 2 | — | 0 | — | — | — |
| maridebart cafraglutide | Phase 2 | Phase 3 | 15 | January 21, 2027 NCT06858878 | Amgen | — |
| marlumotide | Phase 2 | — | 0 | — | — | — |
| mazdutide | Phase 3 | Phase 4 | 16 | April 2027 NCT07843862 | West China Hospital, Tongji Hospital | — |
| mertiatide | Approved (phase 4) | — | 0 | — | — | 1990 |
| mibenratide | Phase 2 | — | 0 | — | — | — |
| mifamurtide | Approved (phase 4) | Phase 2 | 2 | July 31, 2033 NCT07787429 | UNICANCER, Anna Raciborska | 2009 |
| mifamurtide acid | Approved (phase 4) | — | 0 | — | — | 2009 |
| mifomelatide | Phase 2 | Phase 2 | 1 | October 2027 NCT06937177 | Endevica Bio | — |
| milpocitide | Phase 2 | — | 0 | — | — | — |
| modimelanotide | Phase 2 | — | 0 | — | — | — |
| montirelin | Phase 2 | — | 0 | — | — | — |
| motixafortide | Approved (phase 4) | Phase 4 | 6 | December 31, 2026 NCT07101445 | Guangzhou Gloria Biosciences Co., Ltd., Emory University | 2023 |
| murabutide | Phase 2 | — | 0 | — | — | — |
| nacartocin | Phase 2 | — | 0 | — | — | — |
| nafarelin | Approved (phase 4) | Phase 4 | 3 | September 2027 NCT06150703 | Fundacion Dexeus, Assistance Publique - Hôpitaux de Paris | 1990 |
| nangibotide | Phase 2 | Phase 2 | 1 | May 9, 2022 NCT04055909 | Inotrem | — |
| navepegritide | Phase 2 | Phase 2 | 3 | August 2027 NCT06732895 | Ascendis Pharma A/S, Ascendis Pharma Growth Disorders A/S | — |
| nemifitide | Phase 2 | — | 0 | — | — | — |
| nerinetide | Phase 3 | — | 0 | — | — | — |
| nesiritide | Approved (phase 4) | Phase 2 | 1 | December 2018 NCT02608996 | Oslo University Hospital | 2001 |
| nisotirostide | Phase 2 | — | 0 | — | — | — |
| noraramtide | Phase 2 | — | 0 | — | — | — |
| norleusactide | Phase 2 | — | 0 | — | — | — |
| nosiheptide | Phase 2 | — | 0 | — | — | — |
| obinepitide | Phase 2 | — | 0 | — | — | — |
| ociltide | Phase 2 | — | 0 | — | — | — |
| octreotide | Approved (phase 4) | Phase 4 | 34 | November 2026 NCT05050942 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Camurus AB | 1988 |
| olatorepatide | Phase 2 | Phase 2 | 3 | November 13, 2026 NCT07431086 | Regeneron Pharmaceuticals | — |
| omramotide | Phase 2 | — | 0 | — | — | — |
| onvitrelin ucalontide | Phase 2 | — | 0 | — | — | — |
| ornipressin | Phase 2 | — | 0 | — | — | — |
| orotirelin | Phase 2 | — | 0 | — | — | — |
| ovemotide | Phase 2 | — | 0 | — | — | — |
| oximbomotide | Phase 2 | — | 0 | — | — | — |
| oxytocin | Approved (phase 4) | Phase 4 | 81 | October 2026 NCT06036004 | University Hospital, Basel, Switzerland, Wake Forest University Health Sciences | 1980 |
| ozarelix | Phase 3 | — | 0 | — | — | — |
| palopegteriparatide | Approved (phase 4) | Phase 3 | 4 | June 2027 NCT07081997 | Ascendis Pharma Bone Diseases A/S, Ascendis Pharma A/S | 2023 |
| paluratide | Phase 2 | — | 0 | — | — | — |
| pancreatic polypeptide | Phase 2 | — | 1 | October 2026 NCT07506369 | University Hospital, Gentofte, Copenhagen | — |
| pareptide | Phase 2 | — | 0 | — | — | — |
| pasireotide | Approved (phase 4) | Phase 4 | 5 | October 29, 2026 NCT05928390 | University Hospital Heidelberg, Helsinki University Central Hospital | 2012 |
| pasireotide diaspartate | Approved (phase 4) | Phase 2 | 1 | October 29, 2026 NCT05928390 | RECORDATI GROUP | 2012 |
| peforelin | Phase 2 | — | 0 | — | — | — |
| pegapamodutide | Phase 2 | — | 0 | — | — | — |
| peginesatide | Approved (phase 4) | — | 0 | — | — | 2012 |
| pegloprastide | Phase 2 | — | 0 | — | — | — |
| pegmispotide | Phase 2 | — | 0 | — | — | — |
| pegsebrenatide | Phase 2 | — | 0 | — | — | — |
| pemvidutide | Phase 2 | Phase 3 | 2 | September 30, 2027 NCT07009860 | Altimmune, Inc. | — |
| pendetide | Phase 2 | — | 0 | — | — | — |
| pentetreotide | Approved (phase 4) | — | 0 | — | — | 1994 |
| pentigetide | Phase 2 | — | 0 | — | — | — |
| peptide t | Phase 2 | Phase 1 | 1 | November 2030 NCT07481136 | Javid Moslehi, MD | — |
| peptide yy human (3-36) | Phase 2 | — | 0 | — | — | — |
| petrelintide | Phase 2 | Phase 3 | 5 | November 12, 2027 NCT07589686 | Hoffmann-La Roche | — |
| pezadeftide | Phase 2 | — | 0 | — | — | — |
| pimelautide | Phase 2 | — | 0 | — | — | — |
| plecanatide | Approved (phase 4) | Phase 2 | 1 | October 18, 2027 NCT07723924 | Bausch Health Americas, Inc. | 2017 |
| pobrolitide | Phase 2 | — | 0 | — | — | — |
| posatirelin | Phase 2 | — | 0 | — | — | — |
| pr1 leukemia peptide vaccine | Phase 3 | — | 0 | — | — | — |
| pralmorelin | Phase 2 | — | 0 | — | — | — |
| pramlintide | Approved (phase 4) | Early phase 1 | 3 | October 2026 NCT07506369 | Boston University, University Hospital, Gentofte, Copenhagen | 2005 |
| prazarelix | Phase 2 | — | 0 | — | — | — |
| protirelin | Approved (phase 4) | — | 0 | — | — | 1976 |
| quazomotide | Phase 2 | — | 0 | — | — | — |
| ramorelix | Phase 2 | — | 0 | — | — | — |
| recanaclotide | Phase 2 | — | 0 | — | — | — |
| redasemtide | Phase 2 | — | 0 | — | — | — |
| relamorelin | Phase 3 | — | 0 | — | — | — |
| retatrutide | Phase 3 | Phase 3 | 11 | October 2026 NCT06297603 | Eli Lilly and Company, Hudson Biotech | — |
| rimtoregtide | Phase 2 | — | 0 | — | — | — |
| rismorelin | Phase 2 | — | 0 | — | — | — |
| rolipoltide | Phase 2 | — | 0 | — | — | — |
| romurtide | Phase 2 | — | 0 | — | — | — |
| rotigaptide | Phase 2 | — | 0 | — | — | — |
| rovatirelin | Phase 3 | — | 0 | — | — | — |
| rusalatide | Phase 2 | — | 0 | — | — | — |
| rusfertide | Phase 3 | Phase 3 | 4 | October 28, 2027 NCT07648030 | Takeda, Protagonist Therapeutics, Inc. | — |
| ruxotemitide | Phase 2 | — | 0 | — | — | — |
| satoreotide tetraxetan | Phase 2 | — | 0 | — | — | — |
| satoreotide trizoxetan | Phase 2 | — | 0 | — | — | — |
| seglitide | Phase 2 | — | 0 | — | — | — |
| selcopintide | Phase 2 | — | 0 | — | — | — |
| selepressin | Phase 2 | — | 0 | — | — | — |
| semaglutide | Approved (phase 4) | Phase 4 | 280 | October 15, 2026 NCT07505303 | Novo Nordisk A/S, Mayo Clinic | 2017 |
| semparatide | Phase 2 | — | 0 | — | — | — |
| seractide acetate | Approved (phase 4) | — | 0 | — | — | 1978 |
| sermorelin acetate | Approved (phase 4) | — | 0 | — | — | 1990 |
| setmelanotide | Approved (phase 4) | Phase 4 | 5 | October 31, 2026 NCT06772597 | Rhythm Pharmaceuticals, Inc., Massachusetts General Hospital | 2020 |
| sinapultide | Phase 2 | — | 0 | — | — | — |
| solnatide | Phase 2 | — | 0 | — | — | — |
| somatorelin | Approved (phase 4) | — | 0 | — | — | — |
| sonefpeglutide | Phase 2 | Phase 2 | 1 | December 2027 NCT04775706 | Hanmi Pharmaceutical Company Limited | — |
| sovatelitide | Phase 3 | — | 0 | — | — | — |
| sucantomotide | Phase 2 | — | 0 | — | — | — |
| sudocetaxel zendusortide | Phase 2 | — | 0 | — | — | — |
| sulglicotide | Phase 2 | — | 0 | — | — | — |
| survodutide | Phase 3 | Phase 3 | 10 | November 30, 2027 NCT07206290 | Boehringer Ingelheim, University Medical Center Groningen | — |
| svn53-67/m57-klh peptide vaccine | Phase 2 | Phase 2 | 3 | March 30, 2029 NCT07169617 | Roswell Park Cancer Institute, National Cancer Institute (NCI) | — |
| tabilautide | Phase 2 | — | 0 | — | — | — |
| tabimorelin | Phase 2 | — | 0 | — | — | — |
| talfirastide | Phase 2 | — | 0 | — | — | — |
| talogreptide mesaroxetan | Phase 2 | — | 0 | — | — | — |
| taltirelin | Phase 2 | — | 0 | — | — | — |
| taspoglutide | Phase 3 | — | 0 | — | — | — |
| tecemotide | Phase 3 | — | 0 | — | — | — |
| technetium (99mtc) apcitide | Approved (phase 4) | — | 0 | — | — | 1998 |
| technetium mertiatide | Approved (phase 4) | — | 0 | — | — | 1990 |
| teduglutide | Approved (phase 4) | Phase 3 | 4 | February 10, 2027 NCT06973304 | International Centre for Diarrhoeal Disease Research, Bangladesh, Takeda | 2012 |
| temurtide | Phase 2 | — | 0 | — | — | — |
| teprotide | Phase 2 | — | 0 | — | — | — |
| teriparatide | Approved (phase 4) | Phase 4 | 14 | December 30, 2026 NCT04589819 | Ditte Hansen, Massachusetts General Hospital | 1987 |
| terlipressin | Approved (phase 4) | Phase 3 | 9 | May 2026 NCT06256432 | Noorik Biopharmaceuticals AG, Institute of Liver and Biliary Sciences, India | 2022 |
| tertomotide | Phase 3 | Phase 3 | 1 | January 2028 NCT05303701 | Samsung Pharmaceutical Co., Ltd. | — |
| tesamorelin | Approved (phase 4) | Phase 2 | 3 | February 14, 2027 NCT07481734 | Massachusetts General Hospital, Johns Hopkins University | 2010 |
| teverelix | Phase 2 | Phase 2 | 2 | September 2027 NCT07457164 | Antev Ltd. | — |
| tifuvirtide | Phase 2 | — | 0 | — | — | — |
| tigapotide | Phase 2 | — | 0 | — | — | — |
| tiplimotide | Phase 2 | — | 0 | — | — | — |
| tirzepatide | Approved (phase 4) | Phase 4 | 162 | October 30, 2026 NCT06861439 | Eli Lilly and Company, Mayo Clinic | 2022 |
| tosactide | Phase 2 | — | 0 | — | — | — |
| tozuleristide | Phase 2 | — | 0 | — | — | — |
| tricosactide | Phase 2 | — | 0 | — | — | — |
| tridecactide | Phase 3 | — | 0 | — | — | — |
| triletide | Phase 2 | — | 0 | — | — | — |
| triptorelin | Approved (phase 4) | Phase 4 | 36 | November 11, 2026 NCT05050084 | H. Lee Moffitt Cancer Center and Research Institute, NRG Oncology | 2000 |
| trofinetide | Approved (phase 4) | — | 1 | June 2027 NCT06705816 | University of Minnesota | 2023 |
| trolamine polypeptide oleate condensate | Approved (phase 4) | — | 0 | — | — | 1958 |
| ucasareotide dasaroxetan | Phase 2 | — | 0 | — | — | — |
| ularitide | Phase 3 | — | 0 | — | — | — |
| ulimorelin | Phase 3 | — | 0 | — | — | — |
| utreglutide | Phase 2 | — | 0 | — | — | — |
| vanutide cridificar | Phase 2 | — | 0 | — | — | — |
| vapreotide | Phase 3 | — | 0 | — | — | — |
| vasoactive intestinal peptide | Phase 3 | — | 0 | — | — | — |
| vasopressin | Approved (phase 4) | Phase 4 | 29 | October 1, 2026 NCT02118467 | Hospital do Coracao, Assistance Publique - Hôpitaux de Paris | 2014 |
| vasopressin tannate | Approved (phase 4) | — | 0 | — | — | 1982 |
| veldoreotide | Phase 2 | — | 0 | — | — | — |
| vensemaglutide | Phase 2 | — | 0 | — | — | — |
| vezocolmitide | Phase 2 | — | 0 | — | — | — |
| vicatertide | Phase 2 | — | 0 | — | — | — |
| vipivotide tetraxetan | Approved (phase 4) | Phase 4 | 38 | October 15, 2026 NCT06894511 | Novartis Pharmaceuticals, University of Washington | 2022 |
| vipivotide tetraxetan gallium | Phase 2 | Phase 2 | 1 | September 1, 2028 NCT06039371 | University of Washington | — |
| vipivotide tetraxetan gallium ga-68 | Phase 2 | Phase 2 | 1 | September 1, 2028 NCT06039371 | University of Washington | — |
| vipivotide tetraxetan lutetium | Approved (phase 4) | Phase 2 | 8 | December 30, 2026 NCT06145633 | Jonsson Comprehensive Cancer Center, University of Washington | 2022 |
| visepegenatide | Phase 2 | — | 0 | — | — | — |
| vorumotide | Phase 2 | — | 0 | — | — | — |
| vosoritide | Approved (phase 4) | Phase 3 | 13 | March 2027 NCT06668805 | BioMarin Pharmaceutical, Andrew Dauber | 2021 |
| vurolenatide | Phase 2 | — | 0 | — | — | — |
| xelafaslatide | Phase 2 | — | 0 | — | — | — |
| zelenectide | Phase 2 | Phase 2 | 4 | March 2028 NCT06225596 | BicycleTx Limited | — |
| zelenectide pevedotin | Phase 2 | Phase 2 | 4 | March 2028 NCT06225596 | BicycleTx Limited | — |
| zendusortide | Phase 2 | — | 0 | — | — | — |
| ziconotide | Approved (phase 4) | — | 3 | September 2027 NCT04321408 | Christian Hospital Northeast Northwest, ESTEVE Pharmaceuticals SAS | 2004 |
| zifogaptide | Phase 2 | — | 0 | — | — | — |
| zoptarelin doxorubicin | Phase 3 | — | 0 | — | — | — |